1. Home
  2. QLYS vs PTCT Comparison

QLYS vs PTCT Comparison

Compare QLYS & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Qualys Inc.

QLYS

Qualys Inc.

HOLD

Current Price

$176.06

Market Cap

6.3B

Sector

Technology

ML Signal

HOLD

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

HOLD

Current Price

$72.90

Market Cap

5.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QLYS
PTCT
Founded
1999
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
5.7B
IPO Year
2012
2006

Fundamental Metrics

Financial Performance
Metric
QLYS
PTCT
Price
$176.06
$72.90
Analyst Decision
Hold
Buy
Analyst Count
13
17
Target Price
$133.08
$80.65
AVG Volume (30 Days)
732.2K
1.2M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
16.99
264.48
EPS
2.91
0.90
Revenue
$321,607,000.00
$264,734,000.00
Revenue This Year
$9.97
N/A
Revenue Next Year
$7.15
$17.70
P/E Ratio
$61.33
$78.96
Revenue Growth
15.32
36.19
52 Week Low
$74.51
$48.86
52 Week High
$201.54
$90.87

Technical Indicators

Market Signals
Indicator
QLYS
PTCT
Relative Strength Index (RSI) 56.10 47.26
Support Level $130.78 $63.29
Resistance Level $199.13 $73.86
Average True Range (ATR) 7.52 2.03
MACD -1.97 0.19
Stochastic Oscillator 8.02 64.68

Price Performance

Historical Comparison
QLYS
PTCT

About QLYS Qualys Inc.

Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

Share on Social Networks: